Showing 1,277 results

Filters Content type: News, Editors' picks, About HIV Topic: New & experimental HIV treatments

News and information about clinical trials and regulatory approval of new medications to treat HIV.

How HIV works

Pathogenic Landscape of HIV

Editor's pick
UCSF Today
21 December 2011
New & experimental HIV treatments

Gilead Files European Marketing Application for the Quad, a Once-Daily Single-Tablet Regimen for the Treatment of HIV Infection

Editor's pick
Gilead press release
21 December 2011
Pharmaceutical industry

Gilead's New HIV Drug Pipeline: What You Need To Know For 2012

Editor's pick
Seeking Alpha
20 December 2011
New & experimental HIV treatments

Testing nasal vaccine for HIV treatment

Editor's pick
Health Canal
19 December 2011
New & experimental HIV treatments

Novel HIV-Associated Diarrhea Drug Crofelemer Goes to FDA for Approval Review

Editor's pick
AIDSMeds.com
15 December 2011
New & experimental HIV treatments

Aethlon Medical Announces HIV-AIDS Research Discovery

Editor's pick
PR Newswire (press release)
15 December 2011
New & experimental HIV treatments

Gilead Announces Two-Year Data From Pivotal Phase 3 Study of Elvitegravir

Editor's pick
Market Watch
9 December 2011
New & experimental HIV treatments

Boosting Agent Cobicistat Comparable to Norvir in Phase III Study

Editor's pick
AIDSMeds
6 December 2011
Pharmaceutical industry

Ending HIV/AIDS: Hedge Funds Believe in These 5 Companies

Editor's pick
Motley Fool
5 December 2011
New & experimental HIV treatments

Europe approves Gilead's HIV combo Eviplera

Editor's pick
Pharma Times
5 December 2011
New & experimental HIV treatments

Nearly 90 Medicines and Vaccines In Development for HIV/AIDS

Editor's pick
Pharmiweb
1 December 2011
Access to healthcare

Mylan Receives Tentative FDA Approval Through PEPFAR for First Heat-Stable, Fixed-Dose Combination of Atazanavir Sulfate and Ritonavir Tablets for HIV/AIDS

Editor's pick
Press release
1 December 2011
New & experimental HIV treatments

Edurant (rilpivirine) approved in European Union

Editor's pick
Janssen press release
29 November 2011
New & experimental HIV treatments

Gilead Sciences Receives European Marketing Authorization for Eviplera

Editor's pick
Business Wire
28 November 2011
Pharmaceutical industry

Complete One-Pill, Once-Daily Prezista-Based HIV Regimen Enters Development

Editor's pick
AIDSMeds
16 November 2011
Pharmaceutical industry

Gilead and J&J expand HIV cocktail partnership

Editor's pick
CNBC
15 November 2011
New & experimental HIV treatments

Ritonavir dose of 50 mg could be sufficient to boost some protease inhibitors, trials needed

News
15 November 2011
Pharmaceutical industry

DFH Pharma Obtains Exclusive Rights to Second-Generation HIV Maturation Inhibitor Program

Editor's pick
DFH press release
1 November 2011
Pharmaceutical industry

Over the Next Decade, the Dominance of Bristol-Myers Squibb Company 's Atripla in the HIV Drug Market Will Be Challenged by Gilead's Quad and Janssen's Complera

Editor's pick
Business Wire
28 October 2011
Pharmaceutical industry

Gilead posts higher profit, seeks Quad approval

Editor's pick
Reuters
27 October 2011
New & experimental HIV treatments

EACS: Does Maraviroc Intensification Promote Better CD4 Cell Recovery?

Editor's pick
HIVandhepatitis.com
27 October 2011
New & experimental HIV treatments

BMS to develop Reyataz fixed-dose pill with Gilead booster drug

Editor's pick
MarketWatch
26 October 2011
Pharmaceutical industry

Gilead At Crucial Stage For Next-Era HIV Meds

Editor's pick
Investor's Business Daily
19 October 2011
Treatment guidelines

US panel updates antiretroviral treatment guidelines

News
18 October 2011